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After antigen stimulation, naive CD4+ helper T cells differentiate 
into effector T cells to participate in the adaptive immune response. 
Interleukin 17 (IL-17)-producing T helper cells (TH-17 cells) have 
been identified as a distinct subset of effector helper T cells that are 
essential in clearing foreign pathogens and inducing tissue inflamma-
tion during autoimmune disease1,2. TH-17 differentiation is directed 
by lineage-specific transcription factors, including RORγt and RORα3, 
and is controlled by the coordinated activity of a series of positive and 
negative regulators4–7. Although the list of molecular regulators of 
TH-17 differentiation is ever growing, possible factors that link the 
generation of TH-17 cells to pathological conditions, such as autoim-
munity, are largely unknown and need to be clarified.
As a prototype of organ-specific autoimmune disease, multiple 
sclerosis is manifested by chronic inflammatory demyelination of the 
central nervous system (CNS) and is one of the foremost causes of 
nontraumatic neurological disability in young adults8,9. The disease 
is clinically heterogeneous, with about 80% of patients developing the 
relapsing-remitting multiple sclerosis (RRMS) subtype10. Because of 
limited understanding of the pathogenesis of multiple sclerosis and 
a lack of sensitive biomarkers, according to the present criteria11, 
the diagnosis of multiple sclerosis still depends on repeated occur-
rence of the disease. In addition, the signs and symptoms of multiple 
sclerosis usually share considerable similarity with those of other 
CNS inflammatory diseases, such as neuromyelitis optica (NMO); 
this leads to considerable therapeutic and diagnostic difficulties. 
CD4+ T cell–mediated autoimmunity has long been accepted as one 
of the most important aspects of multiple sclerosis pathogenesis, 
especially for the early initiation of disease12,13. T helper type 1 (TH1) 
cells, characterized by the production of interferon-γ (IFN-γ), have 
been considered the type of effector helper T cells that mediate the 
pathogenesis of multiple sclerosis; subsequent studies have indicated 
that TH-17 cells are involved and are at least as critical as TH1 cells 
in this pathogenesis. Mice with fewer TH-17 cells are less susceptible 
to experimental autoimmune encephalomyelitis (EAE)14,15, 
and IL-17-expressing T cells have been found in lesions of brain 
tissues from patients with multiple sclerosis16. Despite the lines of 
 evidence described above, the underlying mechanisms of TH-17 
 differentiation, as well as potential clinical applications, including the 
identification of TH-17-related diagnosis markers or the development 
of TH-17-targeting therapeutic approaches for multiple sclerosis, have 
not been established.
MicroRNAs represent a large family of endogenous noncoding 
RNAs that comprise a fundamental layer of post-transcriptional 
regulation of gene expression17. When poorly regulated, microRNAs 
are critically involved in a range of human diseases18,19 and poten-
tially serve as good diagnostic markers20, prognostic markers21 or 
therapeutic targets19. MicroRNAs also participate in the regulation 
of autoimmunity: deficiency in Dicer or Drosha leads to autoimmune 
signs in mice22,23. However, which microRNAs are involved in the 
regulation and control of autoimmune disease is unclear.
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MicroRNA miR-326 regulates TH-17 differentiation 
and is associated with the pathogenesis of  
multiple sclerosis
Changsheng Du1,5, Chang Liu1,5, Jiuhong Kang1,2, Guixian Zhao3, Zhiqiang Ye4, Shichao Huang1, Zhenxin Li3, 
Zhiying Wu3 & Gang Pei1,2
Interleukin 17 (IL-17)-producing T helper cells (TH-17 cells) are increasingly recognized as key participants in various 
autoimmune diseases, including multiple sclerosis. Although sets of transcription factors and cytokines are known to regulate  
TH-17 differentiation, the role of noncoding RNA is poorly understood. Here we identify a TH-17 cell–associated microRNA,  
miR-326, whose expression was highly correlated with disease severity in patients with multiple sclerosis and mice with 
experimental autoimmune encephalomyelitis (EAE). In vivo silencing of miR-326 resulted in fewer TH-17 cells and mild EAE, 
and its overexpression led to more TH-17 cells and severe EAE. We also found that miR-326 promoted TH-17 differentiation by 
targeting Ets-1, a negative regulator of TH-17 differentiation. Our data show a critical role for microRNA in TH-17 differentiation 
and the pathogenesis of multiple sclerosis.
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Here we report that the microRNA miR-326 is critical in regulating 
TH-17 differentiation and hence contributes to the pathogenesis 
of multiple sclerosis. We found that miR-326 mediated TH-17 
 differentiation through translational inhibition of Ets-1 (A000889), 
a negative regulator of TH-17 differentiation. 
Knockdown or overexpression of miR-326 
alleviated or aggravated EAE, respectively. 
In human patients with multiple sclerosis, 
miR-326 expression was upregulated, and 
this correlated with disease severity and 
IL-17 production. Collectively our results sug-
gest that miR-326 is a TH-17 cell–associated 
microRNA that functions in the pathogenesis 
of multiple sclerosis.
RESULTS
Upregulation of miR-326 in patients with multiple sclerosis
By using clinical samples (Table 1), we found that miR-326 expres-
sion was significantly higher in peripheral blood leukocytes (PBLs) of 
patients with RRMS (Fig. 1a) than in those of age-matched controls 
or patients with NMO, an inflammatory demyelinating CNS disease 
with symptoms that considerably overlap those of multiple sclerosis but 
an etiology distinct from that of multiple sclerosis24. Detailed analysis 
showed that PBLs from patients with relapsing multiple sclerosis had 
significantly higher miR-326 expression but those from patients with 
remitting multiple sclerosis did not (Fig. 1b). In contrast, the expres-
sion of seven known immunologically relevant microRNAs showed no 
substantial changes (Supplementary Fig. 1), which suggested a specific 
association of miR-326 expression with relapsing multiple sclerosis. 
More notably, there was even more prominently enhanced miR-326 
expression in the CD4+ T cell population but not in the CD8+ T cell or 
non–T cell populations of patients with multiple sclerosis (Fig. 1c).
CD4+ T cells that participate in multiple sclerosis pathogenesis take 
on the phenotype of TH1 cells, TH2 cells, TH-17 cells or regulatory 
Table 1 Characteristics of patients and controls
Control RRMS NMO
Sample size 42 43 11
Age 44 ± 12.0 39.6 ± 12.7 42.1 ± 13.4
Sex
 Female 20 (47.6%) 21 (48.8%) 7 (63.6%)
 Male 22 (52.4%) 22 (51.2%) 4 (36.4%)
Clinical stage
 Relapsing – 25 5
 Remitting – 18 6
Drug treatment – – –
Relevant information about human subjects recruited for this study. Sample size is 
total number of subjects; age is presented in years ± s.e.m.; sex is total number  
(with percent of group in parentheses); ‘–’ indicates ‘not applicable’.
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Figure 1 Upregulation of miR-326 in patients 
with multiple sclerosis. (a,b) Quantitative  
PCR analysis of miR-326 expression in PBLs 
from normal controls (Ctrl; n = 42) and 
patients with NMO (n = 11) or RRMS  
(n = 43; a) and PBLs from patients with 
relapsing multiple sclerosis (n = 25) or 
remitting multiple sclerosis (n = 18; b).  
MS, multiple sclerosis. (c) Expression of  
miR-326 and Il17a in CD4+ T cells,  
CD8+ T cells and the non–T cell fraction of 
PBLs from patients with relapsing multiple 
sclerosis and controls (n = 7 per group).  
(d) Linear correlation between transcripts of 
miR-326 and various cytokines in  
CD4+ T cells from patients with RRMS  
(n = 12). (e) FISH analysis of transcripts 
of miR-326 and Il17a in CD4+ T cells from 
patients with relapsing multiple sclerosis and 
normal controls. DAPI, DNA-intercalating dye 
(4,6-diamidino-2-phenylindole). Scale bar, 
3 µm. (f) Quantification of the miR-326 and 
Il17a signals in e. IOD, integrated optical 
density. (g) Expression of miR-326, Ifng and 
Il17a in CCR6+ and CCR6− populations 
sorted from multiple sclerosis CD4+ T cells 
(n = 3). Results in a–d,g are normalized to 
those of controls and are presented relative to 
expression of the small nuclear RNA RNU6B 
(for miR-326) or the ‘housekeeping’ gene 
Rpl13a (for cytokines; encodes the ribosomal 
protein L13A). *P < 0.05, **P < 0.01 and 
***P < 0.005, versus control (Student’s t-test). 
Data are representative of two independent 
experiments (mean and s.e.m. in a–d,g).
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T cells (Treg cells), which are specialized in 
the production of IFN-γ, IL-4, IL-17 or 
transforming growth factor-β (TGF-β), 
respectively. We investigated which helper 
T cell subset was associated with miR-326 
upregulation in patients with multiple scle-
rosis. Expression of Il17a, but not of Ifng, Il4 
or Tgfb, increased with miR-326 expression 
(Fig. 1c and Supplementary Fig. 2). We further confirmed the up- 
regulation of Il17a in patients with relapsing multiple sclerosis at 
the protein level by intracellular cytokine staining of CD4+ T cells 
(Supplementary Fig. 3). Linear correlation analysis of transcripts of 
miR-326 and those cytokines in CD4+ T cells for patients with RRMS 
further demonstrated that only Il17a expression correlated well with 
that of miR-326 (Fig. 1d). Consistent with that, by fluorescence in situ 
hybridization (FISH), we found coexpression of miR-326 and Il17a in 
CD4+ T cells of patients with relapsing multiple sclerosis (Fig. 1e,f), 
which showed that miR-326 was expressed in the TH-17 cell popula-
tion. This was further confirmed by the high expression of miR-326 
in CCR6+CD4+ PBLs of patients with relapsing multiple sclerosis 
(Fig. 1g), a population that identifies most human TH-17 cells
25. 
These results demonstrate that TH-17 cells have high expression of 
miR-326 and that miR-326 expression significantly correlates with 
multiple sclerosis severity.
Regulation of EAE development by miR-326
Expression of miR-326 was also higher in CD4+ T cells from mice 
with EAE during the acute phase but decreased to normal expres-
sion when disease remitted (Fig. 2a), similar to what occurs in 
patients with RRMS. To investigate whether manipulation of 
miR-326 can influence the development of EAE, we constructed 
lentiviral vectors for in vivo miR-326 manipulation. We designed 
vectors encoding pre-miR-326 (LV-326), a mutant miR-326 
control (LV-ctrl)  or its specific inhibitor (LV-sponge) and confirmed 
overexpression or active inhibition of miR-326, respectively (Supple-
mentary Fig. 4 and Supplementary Methods). The term ‘sponge’ refers 
to a miR-326-specific decoy target known to suppress endogenous 
miR-326 activity without affecting its transcript amounts26. We 
delivered approximately 2 × 107 transforming units of recombinant 
lentivirus to mice by injection through the tail vein and assessed the 
in vivo efficacy of lentivirus infection 7 d later by quantitative PCR 
analysis of miR-326 expression in various organs (including those of 
the immune system) of LV-326-infected mice and LV-ctrl-infected 
mice. Consistent with published reports27, systemic administra-
tion of lentivirus led to differences in expression of the transgene 
among various organs, with the liver being most susceptible and the 
brain or lungs being least accessible to the virus (Fig. 2b). In organs 
related to the immune system, infection with LV-326 led to two-
fold greater expression of mature miR-326 in spleen and 1.6-fold 
greater expression in the peripheral lymph nodes (subiliac, proper 
axillary and accessory axillary), but we detected little miR-326 overex-
pression in bone marrow or thymus (Fig. 2c). Notably, the peripheral 
T lymphocyte and B lymphocyte population and CD4+ T cell/CD8+ 
T cell ratio in the resting state showed no difference among mice 
infected with those lentiviruses (Supplementary Fig. 5), nor did we 
find substantial differences between naive (CD62L+CD44loCD4+) 
T cells and antigen-experienced (CD62L−CD44hiCD4+) T cells 
(data not shown), which indicates that miR-326 might not affect 
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Figure 2 Regulation of EAE development by 
miR-326. (a–c) Quantitative PCR analysis of 
miR-326 expression in PBLs and CD4+ T cells 
during EAE development (n = 6 mice per group; 
a) or from the brain, lung and liver (b) or bone 
marrow, peripheral lymph nodes, thymus and 
spleen (c) of mice infected with LV-326 or  
LV-ctrl (day 7 after lentivirus administration; 
n = 3 mice per group). Results are normalized 
to those from naive mice (a) or LV-ctrl mice 
(b,c) and are presented relative to RNU6B 
results. (d) Clinical scores for EAE in mice 
infected with lentivirus (n = 9–10 mice per 
group). (e) Histology of paraffin sections of 
spinal cords isolated from lentivirus-infected 
mice (n = 3 mice per group) on day 21 after 
immunization. Arrows indicate inflammatory 
infiltrations; boxed areas in left columns are 
presented enlarged at right. H&E, hematoxylin 
and eosin. Scale bars, 70 µm. (f) Quantification 
of demyelination and spinal cord infiltrates in 
the sections in f, presented as demyelination 
area relative to total analyzed area (left) and 
infiltrates per mm2 (right). *P < 0.05,  
**P < 0.01 and ***P < 0.005, versus control 
(Student’s t-test (a–c,e) or two-way analysis 
of variance followed by Bonferroni’s post-hoc 
test (parametric data) or Mann–Whitney test 
(nonparametric data; d)). Data are from two 
(a–c,e,f) or four (d) independent experiments 
(mean and s.e.m., a–d,f).
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the homeostasis of the T lymphocyte and 
B lymphocyte repertoire in naive mice.
After immunization of lentivirus-infected 
mice with an encephalitogenic peptide of 
myelin oligodendrocyte glycoprotein consist-
ing of amino acids 35–55 (MOG(35–55)) on 
day 7 after virus injection, LV-326-infected 
mice developed severe EAE, whereas LV-
sponge-infected mice had somewhat mild 
EAE, both relative to that of LV-ctrl-infected 
mice (Fig. 2d and Table 2). Histological anal-
ysis of spinal cord sections also showed that LV-326-infected mice 
developed prominent inflammatory infiltration and demyelina-
tion, whereas LV-sponge-infected mice showed mild CNS pathology 
(Fig. 2e,f). To conclusively demonstrate that miR-326 is critical in 
EAE development, we first sought to further verify the expression 
and distribution of the lentiviral transgene in the EAE mice. Because 
of the low multiplicity of infection (<1) limited to systemic lenti- 
viral administration and the resultant very weak fluorescence of green 
fluorescent protein (GFP) for measurement, we did sensitive FISH 
analysis of GFP transcripts (Supplementary Methods). We found 
that the proportion of virus-infected cells in total cell populations 
of PBLs, spleens, draining lymph nodes (DLNs; pooled peripheral 
lymph nodes from subiliac, proper axillary and accessory axillary 
lymph nodes) and CNS infiltrates from virus-infected mice with EAE 
was 45%, 39%, 33% and 51% respectively (Supplementary Fig. 6a–e). 
Notably, the highest transduction efficiency was in the CNS infiltrates 
of mice with EAE, which supports the idea that lentivirus-mediated 
manipulation of miR-326 contributes to altered EAE pathology.
Further analysis showed that the specific transduction efficiency in 
CD4+ T cells, CD8+ T cells and B cells, quantified by the percentage of 
positive infection in each cell subset, was around 50%, 33% and 28% 
respectively (as averaged for PBLs, spleen, DLNs and CNS infiltrates; 
Supplementary Fig. 6a–d,f), which showed the relative selectivity of 
lentivirus infection for CD4+ T cells. There was no obvious differ-
ence in the transduction efficiency of naive and effector CD4+ T cells 
(Supplementary Fig. 7a,c). Moreover, we also confirmed these data by 
flow cytometry (Supplementary Figs. 7b,c and 8). The data presented 
above collectively showed that EAE pathology differed greatly in mice 
efficiently infected by miR-326 or lentivirus encoding its inhibitor, 
which demonstrated that miR-326 expression and function correlated 
with the development of EAE.
Promotion of TH-17 differentiation by miR-326
We then sought to determine whether the difference in EAE pathol-
ogy in the three groups of lentivirus-infected mice was associated 
with altered infiltration of the CNS with effector helper T cells 
(mainly TH-17 and TH1 cells), a hallmark of CNS inflammation 
in EAE. More CD4+ T cells accumulated in the CNS of LV-326-
infected mice, whereas fewer CD4+ T cells were present in mice 
infected with LV-sponge, as measured by CD4 surface staining of 
Table 2 EAE in lentivirus-infected mice
Group Incidence Time of onset Maximum score Score > 3
LV-ctrl 10 of 10 6.9 (± 0.2) 2.2 (± 0.3) 4 of 10
LV-326 9 of 9 6.3 (± 0.2) 3.6 (± 0.3)* 7 of 9
LV-sponge 10 of 10 7.7 (± 1.2) 1.4 (± 0.2)* 1 of 10
Development of EAE in lentivirus-infected mice immunized with MOG (35–55)  
emulsified in complete Freund’s adjuvant.

 Incidence indicates number of mice that 
developed EAE relative to total mice in group; time of onset is presented in days (mean 
± s.e.m.); maximum EAE score is presented as mean (± s.e.m.); far right column is the 
number of mice achieving an EAE score of greater than 3 relative total mice in group.  
*P < 0.05, versus control (Student’s t-test). Data are cumulative results from four  
different experiments.
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Figure 3 In vivo generation of TH-17 cells  
in EAE mice is enhanced by miR-326.  
(a) Quantification of CD4+ T cells in 
mononuclear cell infiltrates isolated from brains 
and spinal cords of lentivirus-infected mice on 
day 21 after immunization. (b) Intracellular 
staining of IL-17 and IFN-γ in the cells in a. 
Numbers in quadrants indicate percent cells  
in the CD4+ gate. (c) Absolute number of 
CD4+IL-17+ (TH-17) cells and CD4+IFN-γ+  
(TH1) cells analyzed in b. (d) Intracellular 
staining of IL-17 and IFN-γ in DLN cells  
isolated from lentivirus-infected mice on  
day 14 after immunization. Numbers in  
quadrants indicated percent CD4+ cells.  
(e) Absolute number of TH-17 and TH1 cells in 
d. (f) Quantitative PCR analysis of gene  
expression in the DLN cells in d, presented 
relative to Rpl13a expression. (g) IL-17 
and TGF-β1 in supernatants of DLN cells 
restimulated in vitro with MOG (35–55;  
20 µg/ml) and assessed at 48 h of culture.  
*P < 0.05 and **P < 0.01, versus control 
(Student’s t-test). Data are from three 
independent experiments (mean and s.e.m.  
in a,c,e,f).
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CNS leukocyte infiltrates (Fig. 3a). Intracellular cytokine staining 
showed that both the frequency and absolute number of TH-17 
cells, but not of TH1 cells, in the CD4
+ population were higher 
in LV-326-infected mice but lower in LV-sponge-infected mice 
(Fig. 3b,c). We also investigated the correlation between IL-17 
production and virus infection in CNS by FISH analysis of Il17a 
and the sequence encoding GFP. This showed that the percent-
age of IL-17-producing cells in the GFP+ population was higher 
in CNS infiltrates from LV-326-infected mice but lower in those 
from LV-sponge-infected mice. In contrast, the percentage of 
IL-17-producing cells was similar among GFP− cells in all samples 
examined (Supplementary Fig. 9). These data collectively indicate 
that miR-326 functions in EAE development largely by affecting 
the TH-17 cell population.
Next we examined effector T cells primed in peripheral lymph 
nodes from EAE mice in which miR-326 expression had been manipu-
lated. We found more TH-17 cells in DLNs of LV-326-infected mice 
and fewer in those of LV-sponge-infected mice than in those of con-
trol mice. In contrast, TH1 cell numbers were similar in the various 
groups of mice (Fig. 3d,e). Consistent with that, genes specific for the 
TH-17 lineage, including Il17a, Il17f, Il22, Il21 and Il23r, were signifi-
cantly upregulated in LV-326-infected mice and downregulated in 
LV-sponge-infected mice, whereas genes related to other helper 
T cell subsets, such as Ifng, Il4 and Tgfb, were unchanged in 
LV-326- and LV-sponge-infected mice relative to their expression 
in LV-ctrl-infected mice (Fig. 3f). Antigen-specific TH-17 responses 
in DLN cells from LV-326- or LV-sponge-infected mice were higher 
and lower, respectively, as shown by measurement of IL-17 in culture 
supernatants of DLN cells after in vitro restimulation with MOG 
(35–55) (Fig. 3g). Production of the Treg cell–related cytokine TGF-
β was not obviously affected by miR-326 (Fig. 3g). In addition, IL-17 
expression in CD8+ T cells as well as in γδ T cells did not differ among 
mice infected with LV-ctrl, LV-326 or LV-sponge (Supplementary Fig. 10). 
Collectively these data suggest that miR-326 regulates the in vivo  
generation of TH-17 cells during EAE.
To directly assess if miR-326 regulated the differentiation of 
TH-17 cells, we did an in vitro T cell–differentiation assay. By compar-
ing miR-326 expression in all subsets of helper T cells with that in 
naive CD4+ T cells, we found large amounts of miR-326 (17.4-fold 
more than that in naive CD4+ T cells) ‘preferentially’ in TH-17 cells 
but relatively small and similar amounts in TH1, TH2 and inducible 
Treg cells (about 1.6-fold to 3.3-fold more than that in naive CD4
+ T 
cells; Fig. 4a). As a control for in vitro differentiation, we measured 
lineage-specific transcription factors and cytokines (Supplementary 
Fig. 11a,b). CCR6+ cells from in vitro TH-17 cell cultures had approx-
imately fivefold higher miR-326 expression than did their CCR6− 
counterparts (Fig. 4b), along with the enrichment of Il17a expres-
sion (Supplementary Fig. 11c). Again these data indicated that 
miR-326 expression is associated with mouse TH-17 cells as with 
human TH-17 cells. We then purified naive CD4
+CD62L+ helper 
T cells from spleens of mice infected with LV-ctrl, LV-326 or 
LV-sponge and primed the cells for TH-17 differentiation in vitro. 
We found 2.5-fold more miR-326 expression in T cells from LV-326-
infected mice  (Fig. 4c). More TH-17 cells were produced by naive CD4
+ 
T cells from LV-326-infected mice and fewer were produced by those 
from LV-sponge-infected mice (Fig. 4d). The expression of TH-17- 
lineage marker genes (Rorc and Il17a) and IL-17 in culture supernatants 
were also greater with miR-326 overexpression. In contrast, these TH-17 
lineage markers were downregulated in T cells from LV-sponge-treated 
mice after culture in the same conditions (Fig. 4e,f). Expression of 
IL-10, an anti-inflammatory cytokine also induced by TH-17 cells, 
however, was not affected by miR-326 expression (Fig. 4e). The broadly 
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Figure 4 Promotion of in vitro TH-17 
differentiation by miR-326. (a–c) Quantitative 
PCR analysis of miR-326 expression in TH0, 
TH1, TH2, TH-17 and inducible Treg cells 
differentiated in vitro (a), flow cytometry–sorted 
(left) CCR6+CD4+ and CCR6−CD4+ T cells from 
in vitro TH-17 cultures (b), and purified naive 
CD4+CD62L+ T cells of lentivirus-infected  
mice (c; n = 2 mice per group); results are 
presented relative to RNU6B expression.  
(d–f) Intracellular staining of IL-17 (d), 
quantitative PCR analysis of the expression  
of Rorc, Il17a and Il10 (e) and enzyme-linked 
immunosorbent assay (ELISA) of IL-17 in 
culture supernatants (f) of naive CD4+  
CD62L+ T cells obtained from lentivirus-
infected mice and cultured for 4 d in  
TH-17-polarizing conditions. Numbers in 
quadrants (d) indicate percent IL-17+IFN-γ− 
cells (top left) or IL-17−IFN-γ+ cells (bottom 
right). (g–i) Intracellular staining of IL-17 (g), 
quantitative PCR analysis of the expression of 
Rorc, Il17a, Il10 and miR-326 (h) and  
ELISA of IL-17 in culture supernatants  
(i) of naive C57BL/6 CD4+CD62L+ T cells 
cultured for 20 h in ‘TH0’ conditions  
(antibody to IL-4 (anti-IL-4) plus anti-IFN-γ 
but no additional cytokines) and transfected 
by nucleofection with the microRNA inhibitor 
LNA-anti-miR-326 or ‘scrambled’ control 
antisense oligonucleotide (LNA-ctrl),  
followed by TH-17 polarization for another 4 d. Numbers in outlined areas (g) indicate percent IL-17+ cells in the CD4+ gate. *P < 0.05, **P < 0.01 
and ***P < 0.005, versus control (Student’s t-test). Data are from three (a,b,g–i) or two (c–f) experiments (mean and s.e.m., a–c,e,f,h,i).
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used microRNA inhibitor LNA-anti-miR-326 (a locked nucleic acid–
 modified antisense oligonucleotide directed against miR-326) pro-
duced an inhibitory effect on TH-17 differentiation similar to that of 
 infection with LV-sponge (Fig. 4g–i). We also differentiated TH-17 cells 
in vitro with a bicistronic retrovirus encoding miR-326, an internal 
ribosomal entry site and GFP. Relative to infection by control retrovi-
rus (encoding mutant miR-326), transduction of miR-326-encoding 
virus resulted in a substantially higher percentage of IL-17-expressing 
cells in the GFP+ population, whereas infection with virus encoding 
a specific inhibitor of miR-326 resulted in a much lower percentage 
of IL-17-expressing GFP+ cells. In contrast, these groups had a 
similar percentage of IL-17-producing cells among cells gated in 
the GFP− population (Supplementary Fig. 12). Together these data 
 demonstrate that miR-326 positively regulates TH-17 differentiation 
both in vivo and in vitro.
To determine whether the effects of miR-326 on EAE development 
were due to its effect on TH-17 differentiation, we infected mice with len-
tivirus and induced EAE. We collected splenocytes on day 14 after EAE 
induction and restimulated them in vitro for 96 h with MOG  (35–55). 
We purified enriched MOG-specific CD4+ T cells and transferred them 
into sublethally irradiated naive C57BL/6 mice by intravenous injection. 
The resultant EAE scores showed that mice given MOG-specific T cells 
from LV-326-infected donors had more severe disease, whereas mice 
transferred with LV-sponge-infected donor T cells showed less-severe 
signs. Thus, miR-326 expression by CD4+ T cells strongly correlated 
with EAE development (Supplementary Fig. 13).
Ets-1 is a functional target of miR-326
We then applied the prediction programs TargetScan28 and 
miRanda29 to identify the potential miR-326 targets. Two reported 
negative regulators of TH-17 differentiation, Ets-1 (ref. 7) and 
Foxp3 (A002750)6, have putative miR-326-binding elements in their 
3′ untranslated regions (UTRs). We found that miR-326 inhibited 
the luciferase activity of a reporter containing the wild-type Ets1 
3′ UTR but not that of a reporter with a mutated 3′ UTR unable 
to bind miR-326 (Fig. 5a,b). However, miR-326 did not inhibit the 
luciferase activity of the reporter containing the wild-type Foxp3  
3′ UTR (Supplementary Fig. 14a,b), nor did miR-326 affect the TGF-
β1-driven induction of Foxp3 in naive CD4+ T cells isolated from mice 
infected with lentivirus expressing miR-326 or producing ‘knockdown’ 
of miR-326 (Supplementary Fig. 14c), which indicates that miR-326 
specifically targets Ets-1. Consistent with that, miR-326 suppressed 
the expression of Ets-1 protein encoded by a wild-type Ets1 3′ UTR in 
a dose-dependent way (Fig. 5c). Manipulation of miR-326 in CD4+ 
T cells by LNA-anti-miR-326, LV-326 or LV-sponge regulated the 
amount of endogenous Ets-1 protein but did not affect Ets1 transcripts 
(Fig. 5d,e), which indicates that miR-326 functions at the translational 
level. Moreover, there was a similar inverse correlation between the 
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Figure 5 Ets-1 is a functional target of  
miR-326. (a) Mutations in the Ets1 3′ UTR 
(top) and miR-326 (bottom). (b) Luciferase 
activity of reporter carrying the mutated  
(Mut) or wild-type (WT) Ets1 3′ UTR 
cotransfected into HEK293T cells with wild-
type miR-326 or its mutant. (c) Immunoblot 
analysis of hemagglutinin (HA) in HEK293T 
cells expressing a hemagglutinin-tagged 
wild-type Ets-1 3 UTR construct (HA–Ets-
1-3 UTR) or Ets-1 3 UTR with a mutated 
recognition element (3′ UTR-MRE), along 
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transfected or transfected with LNA-anti-miR-
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and quantification of Ets-1 protein in CD4+ 
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scores of EAE in mice coinfected with various  
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fluorescent protein. (k) Immunoblot analysis 
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in the CD4+ gate. (m) Quantification of CNS 
TH-17 cells from the mice in j. Actin serves as 
a loading control throughout. *P < 0.05,  
**P < 0.01 and ***P < 0.005, versus  
control (Student’s t-test). Data are from  
three (b,c,e–i), six (d) or four (j–m) 
independent experiments (mean and s.e.m.  
in b,d,g,i,j,m).
 
 
©
20
09
 N
at
ur
e 
A
m
er
ic
a,
 
In
c.
 
 
A
ll 
rig
ht
s 
re
se
rv
ed
.
1258	 volume 10 number 12 december 2009 nature immunology
expression of miR-326 and Ets-1 in CD4+ T cells from mice with EAE 
and those from patients with multiple sclerosis (Fig. 5f–i).
To directly prove that Ets-1 is a functional target of miR-326 in the 
pathogenesis of multiple sclerosis, we did ‘rescue’ experiments with 
an Ets-1-expressing lentivirus containing mutated sequence encod-
ing the recognition element of miR-326 (LV–Ets-1–3′ UTR-MRE). 
Transduction with LV–Ets-1–3′ UTR-MRE produces Ets1 mRNA 
that is resistant to miR-326-mediated translational inhibition. 
Compared with mice infected with LV-ctrl, mice infected with 
LV-326 showed aggravated EAE, whereas this aggravation was 
completely abrogated by coinfection with LV–Ets-1–3′ UTR-MRE. 
Thus, restoration of Ets-1 protein reversed the effect of miR-326 
(Fig. 5j,k). Flow cytometry analysis of cytokine production by 
CNS-infiltrating CD4+ T cells further supported the idea that Ets-1 
is the functional target of miR-326 during TH-17 differentiation and 
the pathogenesis of multiple sclerosis (Fig. 5l,m).
DISCUSSION
TH-17 cells are critically involved in the pathogenesis of chronic autoim-
mune diseases, including multiple sclerosis30, and regulators of TH-17 
differentiation are considered to have valuable potential for clinical 
applications in the diagnosis or treatment of this category of compli-
cated immune disorders31. Here we have reported a microRNA (miR-
326) that is critically involved in the pathogenesis of multiple sclerosis 
and EAE by regulating TH-17 differentiation. We have shown that miR-
326 expression in CD4+ T cells correlated well with disease in patients 
with relapsing multiple sclerosis and, moreover, its inhibition substan-
tially ameliorated disease severity in the EAE model. Mechanistically, 
we have proven that by targeting Ets-1, a known negative regulator of 
TH-17 cells, miR-326 promoted the generation of TH-17 cells both in 
vivo and in vitro, and this was reversed by the reintroducion of an Ets1 
gene generated to be resistant to miR-326 suppression.
Our data suggest miR-326 is a TH-17-associated microRNA, on the 
basis of the following observations. First, miR-326 expression corre-
lated well with IL-17 expression in patients with multiple sclerosis. 
Second, the FISH assay of miR-326 and Il-17a in CD4+ T cells from 
patients with multiple sclerosis and their enrichment in CCR6+CD4+ 
T cells showed that the peripheral blood of patients with relapsing 
multiple sclerosis had more IL-17-expressing CD4+ T cells, with high 
expression of miR-326 in these cells. Upregulation of miR-326 was 
associated only with multiple sclerosis, as patients with NMO, another 
CNS inflammatory disorder similar to multiple sclerosis but mediated 
by antoantibodies, showed no miR-326 upregulation in PBLs32. Third, 
in the in vitro differentiation model, TH-17 cells had higher expression 
of miR-326 than did TH1, TH2 or inducible Treg cells. Finally, miR-326 
was functionally involved in TH-17 differentiation both in vitro and 
in vivo. Our findings may provide a new target for manipulating the 
generation of TH-17 cells in related diseases. Further exploration of 
the function of miR-326 in other cell types, especially those of the 
innate immune system, will be of great importance for understanding 
the cell-differentiation network of the immune system.
Generally, microRNAs are believed to function in vivo by target-
ing multiple functionally related proteins or a key protein target33,34. 
In the immune system, miR-181 controls T cell antigen receptor 
signaling strength during T cell maturation by downregulating a 
set of negative regulators35, whereas miR-150, the hematopoiesis-
 specific microRNA, controls embryonic development and B cell 
differentiation by regulating a key target, c-Myb36,37. Our data suggest 
miR-326 regulates TH-17 cells mainly by targeting Ets-1. As a functional 
miR-326 target, Ets-1 therefore represents a distinct regulator of 
TH-17 differentiation. Although published work has shown that 
Ets-1 restrains TH-17 differentiation without affecting the induction 
of RORγt7, the lineage-defining transcription factor of TH-17 cells, 
the mechanisms regulating its own expression and the physiological 
relevance of Ets-1 have remained largely unclear. Our study has now 
shown that Ets-1 expression was substantially downregulated by 
miR-326 in patients with relapsing multiple sclerosis. Moreover, the 
greater disease severity and greater number of TH-17 cells in LV-326-
infected mice was largely reversed by coinfection of these mice with 
lentivirus expressing Ets1 with a mutated 3′ UTR. This indicates Ets-1 
indeed acts as a key target of miR-326, at least in the development of 
EAE and multiple sclerosis.
The immunosuppressive drugs now approved for the clinical treat-
ment of multiple sclerosis work mainly by increasing the frequency of 
Treg cells or by changing the TH1-TH2 bias
38. Drugs that target TH-17 
cells, however, have not yet been applied to multiple sclerosis therapy. 
We found that miR-326 was substantially downregulated in a group of 
patients after glucocorticoid treatment (data not shown), the routine 
therapy for patients with multiple sclerosis to relieve symptoms caused 
during an acute relapse39, which indicates that miR-326 expression itself 
not only correlates well with disease severity and the relapsing phase of 
multiple sclerosis but also is under the regulation of disease-modifying 
drugs or environmental factors in patients with multiple sclerosis. 
Combined with the findings that specific and inversely correlated up- 
or downregulation of the expression of miR-326 and Ets-1 was easily 
detected in blood samples from patients with multiple sclerosis, our 
results suggest that this microRNA-protein pair is of potential value as 
a biomarker for the diagnosis of multiple sclerosis disease, assessment 
of its prognosis or evaluation of drug responses. Also, elucidation of the 
specific signals that regulate miR-326 expression in disease will deepen 
the knowledge of how this noncoding RNA–mediated mechanism con-
tributes to the pathogenesis of multiple sclerosis and help to identify 
new therapeutic approaches by targeting miR-326 for multiple sclerosis 
treatment. In summary, miR-326 may serve as a new and valuable target 
for clinical applications in patients with multiple sclerosis.
METHODS
Methods and any associated references are available in the online version 
of the paper at http://www.nature.com/natureimmunology/.
Accession codes. UCSD-Nature Signaling Gateway (http://www. 
signaling-gateway.org): A000889 and A002750.
Note: Supplementary information is available on the Nature Immunology website.
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ONLINE METHODS
Study subjects. Subjects were patients from the outpatient clinic of Huashan 
Hospital (Shanghai, China) with clinically defined RRMS or NMO or age- and 
sex-matched healthy volunteers from personnel of the Institute of Biochemistry 
and Cell Biology. Blood samples were obtained from subjects after informed 
consent was provided and the sampling was completed in accordance with the 
guidelines of local institutional review boards.
Mice. C57BL/6 mice were from the Shanghai Laboratory Animal Center 
(Chinese Academy of Sciences). Protocols for animal experiments were 
approved by the institutional animal use committee of the Shanghai Institutes 
for Biological Sciences (Chinese Academy of Sciences). All mice were main-
tained in pathogen-free conditions.
Reagents. The following antibodies were from BD Pharmingen: fluorescein 
isothiocyanate–conjugated anti–mouse CD3ξ (145-2C11), anti–mouse CD4 
(L3T4), anti–mouse CD8a (53-6.7), anti–mouse CD19 (1D3) and anti–mouse 
CD62L (MEL-14); phycoerythrin-conjugated anti–mouse CD45R (B220; 
RA3-6B2) and anti–mouse IL-17 (TC11-18H10.1); phycoerythrin–cyanine 
5.5–conjugated anti–mouse CD44 (IM7); and anti-CD16-CD32 (2.4G2). 
Phycoerythrin-indotricarbocyanine–conjugated anti–mouse CD4 (L3T4), 
allophycocyanin-conjugated anti–mouse IFN-γ (XMG1.2), phycoerythrin-
conjugated anti-Foxp3 (FJK-16S) and allophycocyanin-conjugated anti–
human CD4 (eBio64DEC17) were from eBiosciences. Secondary antibodies 
anti-Ets-1 (sc-350; Santa Cruz) and IRDye 800CW–conjugated affinity- 
purified anti–rabbit immunoglobulin G (600-431-384; Rockland) were used 
for immunoblot analysis.
Lentivirus-mediated overexpression or inhibition of miR-326. A genomic 
sequence spanning the mouse miR-326 coding region flanked by approxi-
mately 100 base pairs from 5′ or 3′ on either end was cloned, downstream of 
the cytomegalovirus promoter, into a modified lentiviral vector generated from 
pCDH-CMV-MCS-EF1-copGFP (CD511B-1; System Bioscience), in which 
EF1-copGFP was replaced with IRES-eGFP. For control or miR-326 inhibi-
tion, sequence encoding mutant miR-326 or its specific inhibitor (sponge) was 
cloned into the same vector. Virus was produced and target cells were infected 
according to the user’s manual.
T cell purification and activation. Naive CD4+CD62L+ helper T cells 
were prepared by magnetic cell sorting from spleens of female C57BL/6 
mice 6–8 weeks of age. Sorted cells were activated with anti-CD3 (2 µg/ml; 
145-2C11, soluble; BD Pharmingen) and anti-CD28 (2 µg/ml; 37.51, soluble; 
BD Pharmingen) and were induced to differentiate into TH1 cells by sup-
plementation with IL-12 (10 ng/ml; Peprotech) plus anti-IL-4; into TH2 cells 
with IL-4 (40 ng/ml plus anti-IFN-γ; or into inducible Treg cells with TGF-β1 
(5 ng/ml; Peprotech) and recombinant mouse IL-2 (50 U/ml; peprotech) plus 
anti-IFN-γ. Cells stimulated in ‘neutral’ conditions (anti-IL-4 plus anti- IFN-γ 
but no additional cytokines) were considered ‘TH0’ cells. For TH-17 differentia-
tion, cells usually received anti-IL-4 and anti-IFN-γ plus a TH-17 ‘cocktail’ con-
taining TGF-β1 (3 ng/ml), IL-6 (30 ng/ml; eBioscience), tumor necrosis factor 
(10 ng/ml; Peprotech) and IL-1β (10 ng/ml; Peprotech). Neutralizing anti-
IFN-γ (XMG1.2; BD Pharmingen) and anti-IL-4 (11B11; BD Pharmingen) 
were each used at a concentration of 10 µg/ml.
EAE. The encephalitogenic peptide MOG (35–55) (GLBiochem) used 
to induce EAE had a purity of 95%. For EAE induction, female C57BL/6 
mice 6–8 weeks of age were immunized subcutaneously with 150 µg 
MOG (35–55) in complete Freund’s adjuvant containing heat-killed 
Mycobacterium tuberculosis (H37Ra strain; 5 mg/ml; BD Diagnostics). 
Pertussis toxin (200 ng per mouse; Calbiochem) in PBS was administered 
intraperitoneally on day 0 and day 2. Mice were examined daily for disease 
signs by researchers ‘blinded’ to experimental conditions and were assigned 
scores on a scale of 0–5 as follows40: 0, no clinical signs; 1, paralyzed tail; 2, 
paresis (weakness, incomplete paralysis of one or two hindlimbs); 3, paraplegia 
(complete paralysis of both hindlimbs); 4, paraplegia with forelimb weakness 
or paralysis; and 5, moribund state or death. For analysis of central nervous 
system infiltrates, brain and spinal cord tissues were collected from perfused 
mice and mononuclear cells were prepared by Percoll gradient centrifugation. 
For histological analysis, the same tissue samples were immediately fixed in 
4% (wt/vol) paraformaldehyde. Paraffin-embedded sections of spinal cord 
were stained with hematoxylin and eosin or with Luxol fast blue for analysis 
of inflammation or demyelination, respectively.
Intracellular staining and flow cytometry. For intracellular cytokine stain-
ing, cells obtained from in vitro culture or from DLNs or CNS infiltrates 
of mice with EAE were incubated in a tissue culture incubator for 5 h at 
37 °C with phorbol 12-myristate 13-acetate (50 ng/ml; Sigma), ionomycin 
(750 ng/ml; Sigma) and brefeldin A (10 µg/ml; Sigma). Surface staining 
was done as described above with the corresponding fluorescence-labeled 
surface antibodies. After surface staining, cells were resuspended in Fixation/
Permeabilization solution (Cytofix/Cytoperm kit; BD Pharmingen) and intra-
cellular cytokine staining was done according to the manufacturer’s protocol. 
For Foxp3 staining, cells were not stimulated with phorbol 12-myristate 
13-acetate and ionomycin; instead, the protocol for the Foxp3 Staining Buffer 
set was followed (eBioscience). A FACSCalibur and CellQuest software or an 
LSR II and FACSDiva (BD Biosciences) were used for flow cytometry.
Oligonucleotide transfection. An antisense oligonucleotide modified 
by locked nucleotide acid (LNA; Dharmacon) was synthesized to inhibit 
miR-326. Primary mouse CD4+ T cells were transfected by nucleofection 
(program X-01; Amaxa) with 50 nM LNA-anti-miR-326 or the ‘scrambled’ 
control at 20 h after activation.
Luciferase reporter assay. HEK293T cells (American Type Culture Collection) 
were maintained in DMEM (Gibco-BRL) and cells of 50% confluence in 
24-well plates were transfected with Fugene HD reagent (Roche). A firefly 
luciferase reporter gene construct (200 ng per well) and pRL-SV40 Renilla 
luciferase construct (1 ng per well; for normalization) were cotransfected. Cell 
extracts were prepared 24 h after transfection and luciferase activity was meas-
ured with the Dual-Luciferase Reporter Assay system (Promega). Wild-type or 
mutated 3′ UTR sequences of Ets1 or Smo (encoding smoothened) were cloned 
into the modified pGL3-control vector (Promega) as described41.
ELISA. Cytokines in culture supernatants after in vitro stimulation were 
quantified by ELISA according to the manufacturer’s instructions as 
follows: for mouse IL-17 and IFN-γ, R&D Systems; for mouse TGF-β1, 
Genetimes Technology.
Statistics. A two-tailed Student’s t-test was applied for statistical comparison 
of two groups, or where appropriate, the two-way analysis of variance followed 
by Bonferroni’s post-hoc test for multiple comparisons and a Mann–Whitney 
test for nonparametric data (EAE scoring). A P value of 0.05 or less was 
considered significant.
40. Stromnes, I.M. & Goverman, J.M. Active induction of experimental allergic 
encephalomyelitis. Nat. Protoc. 1, 1810–1819 (2006).
41. Chen, J.F. et al. The role of microRNA-1 and microRNA-133 in skeletal muscle 
proliferation and differentiation. Nat. Genet. 38, 228–233 (2006).
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Corrigendum: MicroRNA miR-326 regulates TH-17 differentiation and is 
associated with the pathogenesis of multiple sclerosis
Changsheng Du, Chang Liu, Jiuhong Kang, Guixian Zhao, Zhiqiang Ye, Shichao Huang, Zhenxin Li, Zhiying Wu & Gang Pei
Nat. Immunol. 10, 1252–1259 (2009); published online 18 October 2009; corrected after print 4 December 2009
In the version of this article initially published, the Actin loading control blot for the top blot is missing from Figure 5c. The error has been cor-
rected in the HTML and PDF versions of the article.
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